Filana Therapeutics reports 2025 net loss of $91M; cash burn guidance and TSC program clinical hold detailed

FILANA THERAPEUTICS, INC.

Net loss $91.0M ($1.88/share) vs $24.3M ($0.53) in 2024; cash $95.5M at Dec 31, 2025.
Est. cash at June 30, 2026 at $47-50M; net cash use H1 2026 $14-17M plus $31.25M litigation settlement payment.
R&D expenses fell 62% to $26.6M after Alzheimer's program phase-out; TSC program on clinical hold since Dec 2025.
G&A expenses $68.8M include $31.3M securities litigation contingency; no insurance recoveries.
Name change to Filana Therapeutics reflects focus on filamin A modulation for TSC-related epilepsy.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

FILANA THERAPEUTICS, INC. reported the fourth quarter and year ended December 31, 2025 results: net income Net loss for 2025 was $91.0 million, EPS $1.88 per share.

Period: the fourth quarter and year ended December 31, 2025
Net income: Net loss for 2025 was $91.0 million
EPS: $1.88 per share
Result: reported results

Exact text from the filing

Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

View on SEC.gov

Browse all earnings releases →

FILANA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001171843-26-001506

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.